Enterprise Value
5.487B
Cash
538.3M
Avg Qtr Burn
-11.69M
Short % of Float
17.43%
Insider Ownership
12.67%
Institutional Own.
99.18%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VYJUVEKTM (B-VEC) (Topical Beremagene Geperpavec) Details Skin disease/disorder, Dystrophic epidermolysis bullosa, Epidermolysis bullosa | Approved Quarterly sales | |
Ophthalmic B-VEC Details Dystrophic epidermolysis bullosa | Phase 1/2 Initiation | |
KB105 Details Autosomal recessive congenital ichthyosis , Skin disease/disorder | Phase 1/2 Initiation | |
KB707 (IL-2 and IL-12) Details Solid tumor/s, Multiple tumors, Cancer | Phase 1 Data readout | |
KB408 Details Severe alpha-1 antitrypsin deficiency | Phase 1 Data readout | |
KB301 Details Wrinkles | Phase 1 Data readout | |
Inhaled KB707 Details Solid tumor/s, Lung Metastases, Cancer | Phase 1 Update | |
KB407 Details Cystic fibrosis | Phase 1 Initiation |